ADQ acquires Turkish pharmaceutical leader Birgi Mefar Group

  • ADQ acquires Turkey’s leading contract development and manufacturing company (CDMO) of sterile solutions and injectables
  • Investment Expands ADQ’s Life Sciences Capabilities in Sterile Injectables and Broader Pharmaceutical Services Segments, While Complementing its Broader Engagement in Turkey

Abu Dhabi, UAE: ADQ, an Abu Dhabi-based investment and holding company, today announced that it has entered into a definitive agreement to acquire Birgi Mefar Group (BMG), one of Turkey’s leading producers of sterile injectable products.

As a full-service pharmaceutical CDMO, BMG is a production service provider of sterile injectable products, namely vials and pre-filled syringes used for vaccines. BMG also produces ampoules and primary packaging vials for other sterile injectables and specializes in the growing demand for lyophilization of drugs. The company exports to over 30 countries including European and Asian markets with over 50 years of expertise and excellence.

Fahad Al Qassim, Executive Director, Healthcare and Life Sciences Portfolio at ADQ, said: “BMG’s diverse offering and manufacturing capabilities make the company a strategic addition to our growing portfolio as we continue to shape the UAE’s healthcare and life sciences platform. Turkey is an important market for our investments, and BMG brings with it a strong presence across the pharmaceutical supply chain, from drug development and manufacturing to cold chain packaging and distribution. . With this integrated capability, we believe it can strengthen local expertise and build on the UAE’s ability to manufacture and distribute quality healthcare products as the region’s leading pharmaceutical hub.

Faik Somer, CEO of Birgi Mefar Group, said: “Joining the ADQ portfolio is an exciting next step in our journey that will elevate our offering and allow us to expand into lucrative markets like the UAE and the wider MENA region. For over 50 years we have been committed to quality healthcare and with the support of the ADQ we will be better positioned to deliver excellence in the development and manufacturing of sterile products on a global scale, which will ultimately generate long-term sustainable growth.

This is part of the ADQ’s efforts to build a fully integrated healthcare and life sciences platform in the UAE. It will provide the ADQ with exposure to a rapidly growing market for injectables and high value-added treatments, such as vaccines, as well as access to a vast network of clients ranging from large multinationals to local and regional players. Additionally, the acquisition will allow BMG to join ADQ’s healthcare and life sciences portfolio which aims to enhance manufacturing, distribution and marketing capabilities, including the provision of healthcare products. sterile and injectable solutions.

Earlier this year, the ADQ acquired Acino, a pharmaceutical manufacturer based in Switzerland and present in more than 90 countries. In 2021, ADQ acquired Pharmax, one of the leading pharmaceutical manufacturers in the United Arab Emirates, and Amoun, one of Egypt’s leading pharmaceutical companies. ADQ also retains a minority stake in Biocon Biologics Limited, India’s largest biopharmaceutical company.

The transaction is subject to customary closing conditions, including regulatory approvals.

About the ADQ

Established in 2018, ADQ is an Abu Dhabi-based investment and holding company with a broad portfolio of large companies. Its investments span key sectors of the UAE’s diverse economy, including energy and utilities, food and agriculture, healthcare and life sciences, mobility and logistics, among others. . As a strategic partner of the Government of Abu Dhabi, the ADQ is committed to accelerating the emirate’s transformation into a globally competitive and knowledge-based economy.


Comments are closed.